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In their recent article, Cunningham et al.
[EHP 104(suppl 3): 683-686 (1996)]
showed that in male B6C3F1 lad trans-
genic mice after 90 days ofdietary adminis-
tration, 2,4-DAT (2,4-diaminotoluene) led
to a twofold increase in mutant frequency
(MO, whereas 2,6-DAT did not. Based on
this, the authors believe that these data help
to validate the transgenic mouse model as a
potential indicator ofcarcinogenic response
and suggest that the Big Blue assay is also
useful for mechanistic studies of carcino-
genicity. We have doubts whether this
belief is really supported by the compiled
information, as can be easily derived from
Table 1.
In our opinion the association ofeffects
allows the following conclusions:
1. Both compounds are mutagenic in
the in vitro S. typhimurium assay. Thus,
both compounds can be considered equal
with regard to their possible tumorigenic
potential.
2. In the Big Blue assay, presence (for
2,4-DAT) or absence (for 2,6-DAT) ofthe
association of proliferation, tumorigenesis,
increase of mutation frequency, and UDS
in the same tissue (liver) is recognized.
However, whether the increase of the
mutation frequency is just a sequela ofthe
proliferative effect (clonic expansion of
mutated cells that are also present in the
negative control group) or a 2,4-DAT-
induced tumorigenic DNA alteration
remains unclear. In order to clarify this
question, the effect of a pure proliferative
stimulus (e.g., partial hepatectomy) should
Table 1.Transgenic mouse models andtestresults
Results(qualitative) for
Testsystems 2,4-DAT 2,6-DAT
In vitro mutagenicity + +
(S. typhimurium)
Proliferative forlivertissue + -
Livertumorigenic + -
Increase ofMfinthe + -
Big Blue assay
In vivo-in vitroUDS in livercells +-
have been investigated in an additional
group. Hence, it follows that liver tumori-
genicity of 2,4-DAT might be causally
linked either to its proliferative or its muta-
genic effect or to both. Additionally, it is
still questionable whether the described
effect reflects a genuine mutagenic
response, since the mutation frequencies
induced by 2,4-DAT are quite similar after
30-day (Mf:9,3 x 10-5) and 90-day treat-
ment (12,1 x 10-5). The statistical signifi-
cance reported is mainly based on the
lower spontaneous rate observed in the
control group after 90-day treatment
(Mf:5,7 x 10-5) in comparison to 30-day
treatment (12,1x10-5). Thus, in our opin-
ion, the Big Blue assay does not in this par-
ticular case provide more insight into the








In their letter and table, Drs. Gunzel and
Reimann make three points concerning
our recent publication [EHP 104(suppl
3):683-686 (1996)]. First, conclusion 1
states that compounds that are mutagenic
in S. typhimurium should be "considered
equal with regard to their possible tumori-
genic potential." We believe there are few
in the field of mutation research that
would agree with this statement. Indeed,
mechanistic research from our laboratories
and others has focused on the overwhelm-
ing lack of concordance between in vitro
tests and in vivo bioassays. Moreover, we
feel that Drs. Gunzel and Reimann illus-
trate the pressing need for in vivo models
ofmutagenicity that incorporate factors of
physiological relevance such as chemically-
induced cell proliferation. The Big Blue
assay is such a model. Unfortunately, Drs.
Gunzel and Reimann misinterpret the data
shown in their table. 2,6-DAT is not an
hepatocarcinogen in mice or rats at the
same or higher doses than proved hepato-
carcinogenic for 2,4-DAT. Here the S.
typhimurium was not useful in predicting
potential carinogenicity. One must con-
clude that compounds that are mutagenic
in S. typhimurium cannot be necessarily
considered equal with regard to their possi-
ble tumorigenic potential. This is the point
of evaluating chemicals using an in vivo
mutation assay.
Second, Drs. Gunzel and Reimann
argue in conclusion 2 that the increase in
observed mutant frequency (MO could
arise from either 2,4-DAT induced cellular
proliferation or from 2,4-DAT induced
DNA damage. We agree. Further studies
are necessary to define the mechanism
whereby 2,4-DAT is mutagenic in the Big
Blue assay. The point stressed in our man-
uscript, and the clear conclusion from our
study, is that the carcinogen 2,4-DAT
induces mutations in the liver, whereas the
noncarcinogen 2,6-DAT does not.
Finally, Drs. Gunzel and Reimann
question the comparison of induced Mf
data with aged matched controls. We are
not comfortable making any other com-
parison. Indeed, we feel that the compar-
isons made by Drs. Gunzel and Reimann
in conclusion 2 clearly underscore the
importance ofincluding age-matched con-
trols in any in vivo mutagenesis studies.
Thus, we remain confident that our
studies with 2,4-DAT and 2,6-DAT using
the Big Blue assay provide important
insights regarding the relationship between
mutagenesis and carcinogenesis. In addi-
tion, we believe that the development of
the Big Blue and other mammalian in vivo
mutation assays provide a significant
opportunity for mechanistic studies regard-
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